Healid establishes the infrastructure for an efficient market which greatly reduces the cost and increases the quality of the outcome of research and development for about 7000 genetically triggered diseases. Reduced costs and improved output is equivalent to overall tangible value. The challenge is mostly one of scale. This is addressed by Healid.
Currently, similar markets do in very rudimentary form exist, with great limitations, e.g. for clinical studies. Sample sizes often are measured by the dozens, and it is an arduous process to narrow down selections of meaningful subjects. By introducing a bottom-up process and making massive amounts of potentially meaningful data publicly available in an anonymized form, but authorized by individuals as owners, key research processes can be as “simple” as tapping into this database. This introduces almost unlimited scalability, without most of the currently existing restrictions.
At the same time the global scale of Healid does profoundly expand the market size for treatments. Instead of hundreds or thousands, now millions of people can find out about treatment options or cures – or on the flip side of this, researchers and businesses can work for a much larger market, at much lower cost. Economies of scale introduce efficiencies on all levels.
In the medium and long term, the value for society is dramatic: The reduction in research and development costs enables the addressing of risk factors, thus reducing the severity of diseases, or even their onset. Health care costs should significantly be reduced, globally.